Type 2 diabetes Trials in San Antonio, United States
Conditions / Type 2 diabetes / San Antonio, United States
Type 2 diabetes is a medical condition with active clinical research programs worldwide.
120 total trials for this combination
Showing top 10 of 120 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06131372 | A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | COMPLETED | PHASE2 |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT07030868 | A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes | TERMINATED | PHASE2 |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT05872620 | A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT02019264 | A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | COMPLETED | PHASE4 |
| NCT01601574 | Weight Loss Study for People With Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT06945419 | A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes | RECRUITING | — |
| NCT00845182 | Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function | COMPLETED | PHASE4 |